吉西他滨联合消癌平治疗晚期非小细胞肺癌减毒增效的临床研究

Clinical research of combined gemcitabine with Xiaoaiping injection on advanced non - small cell lung cancer ：lower toxidty and higher efficacy

目的探讨吉西他滨联合消癌平注射液对初治晚期非小细胞肺癌（NSCLC）患者的临床疗效和毒副反应。方法晚期NSCLC患者76例（ⅢB-Ⅳ期），分成消癌平联合GP方案组38例（治疗组）和GP方案组38例（对照组），入组的每例患者接受至少2个周期的治疗，比较两组治疗的近期疗效和毒副反应，以及1、2年的生存率。结果GP方案联合消癌平组和GP方案组近期疗效的有效率分别为52．63％和47．36％，两组中位生存期分别为8．9月和8．7月，1年生存率分别为45．2％和43．5％，2年生存率分别为23．4％和22．9％。两组资料差异均无显著性（P〉0．05）。治疗组在生活质量改善方面疗效明显优于对照组（P〈0．05）。毒副反应方面，治疗组和对照组，均在可耐受的范围内。结论吉西他滨联合消癌平注射液治疗晚期非小细胞肺癌有较好的临床疗效，副作用小，有效改善临床症状，可提高患者生活质量和机体免疫功能，值得临床推广应用。

Objective To evaluate the clinical effect and toxicity of combined gemcitabine with Xiaoaiping injection for the initial treatment of advanced non - small cell lung cancer（NSCLC）. Methods 76 cases of advanced NSCLC patients（ Ⅲ B - Ⅳ period）were divided into combined group of Xiaoaiping injection and GP regimen（test group）or GP group（control group）. All the patients had accepted GP regimen or Xiaoaiping injection with GP regimen at least 2 cycles. A clinical observation on short term effectiveness, adverse effects and the 1 - ,2 - year survival rate were carried out in two groups. Results The short term effective rate for advanced NSCLC in GP group and combined group of Xiaoaiping injection and GP regimen was 52.63% and 47.36% ,respectively. The median survival time was 8.9 months and 8.7 months, respectively. 1 - year survival rate was 45.2% and 43.5% ,respectively. 2 - year survival rate was 22.9% and 23.4% ,respectively. The short term effectiveness and the 1 - ,2- year survival rate in two groups had no statistically significant difference（P 〉0.05）. The life quality of patients in test group is superior to the patients in control group （P 〈 0.05 ）. In the adverse effects of treatment,the major cytotoxicity was tolerable. Conclusion Combined gemcitabine with Xiaoaiping injection can improve the curative effect and lower toxicity of advanced non - small cell lung cancer and the patients life quahty,as well as enhancing the immune function.